Market Assessment, Malignant Melanoma Unmet Need US/EU 2016 Report

Since 2011, several novel first-line unresectable or metastatic malignant melanoma therapies have gained approval in the U.S. and in Europe. These agents, namely immunotherapies and BRAF and MEK inhibitors, have revolutionized the treatment landscape of malignant melanoma, considerably improving patients’ survival. Despite the remarkable improvement in survival, the prevailing unmet needs in first-line unresectable or metastatic malignant melanoma therapies still consolidate around the improvements in efficacy, creating a significant clinical and commercial opportunity for drug developers to exploit with new therapies which can extend patients lives.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Malignant Melanoma | Unmet Need | US/EU | 2016

Related Market Assessment Reports

Asthma | Unmet Need | Severe Asthma | US/EU | 2021

Asthma – Unmet Need – Detailed, Expanded Analysis – Severe Asthma (US/EU)

Pulmonary Hypertension – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Crohn’s Disease – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Pediatric Crohn’s Disease (US)

Chronic Kidney Disease – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)